Wall Street brokerages expect Bruker (NASDAQ:BRKR) to post earnings per share (EPS) of $0.22 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Bruker’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.24. Bruker reported earnings per share of $0.19 in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.8%. The firm is expected to issue its next earnings report on Wednesday, May 2nd.

On average, analysts expect that Bruker will report full-year earnings of $1.37 per share for the current financial year, with EPS estimates ranging from $1.36 to $1.41. For the next year, analysts forecast that the company will post earnings of $1.53 per share, with EPS estimates ranging from $1.48 to $1.58. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Bruker.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.02. The company had revenue of $530.50 million during the quarter, compared to the consensus estimate of $506.74 million. Bruker had a net margin of 4.45% and a return on equity of 26.68%. Bruker’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.46 earnings per share.

Several research firms have issued reports on BRKR. Morgan Stanley cut their price target on shares of Bruker from $32.00 to $31.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 11th. BidaskClub raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Leerink Swann lifted their price target on shares of Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a report on Friday, February 9th. Zacks Investment Research lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, BTIG Research began coverage on shares of Bruker in a report on Friday, January 5th. They issued a “buy” rating and a $42.00 price target on the stock. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. Bruker has an average rating of “Hold” and an average price target of $32.54.

Shares of NASDAQ:BRKR opened at $30.66 on Thursday. The company has a market capitalization of $4,785.35, a P/E ratio of 25.13, a price-to-earnings-growth ratio of 2.03 and a beta of 1.12. Bruker has a 52 week low of $21.95 and a 52 week high of $36.53. The company has a quick ratio of 1.66, a current ratio of 2.59 and a debt-to-equity ratio of 0.57.

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 23rd. Stockholders of record on Tuesday, March 6th were issued a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend was Monday, March 5th. Bruker’s dividend payout ratio (DPR) is presently 13.22%.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC grew its holdings in shares of Bruker by 5.7% during the fourth quarter. Acadian Asset Management LLC now owns 5,229,258 shares of the medical research company’s stock valued at $179,467,000 after buying an additional 280,245 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Bruker by 7.1% during the fourth quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock valued at $177,566,000 after buying an additional 341,389 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Bruker by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 1,294,131 shares of the medical research company’s stock valued at $44,414,000 after buying an additional 31,742 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Bruker by 1.3% during the third quarter. Dimensional Fund Advisors LP now owns 921,431 shares of the medical research company’s stock valued at $27,412,000 after buying an additional 11,466 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Bruker by 3.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 597,615 shares of the medical research company’s stock valued at $20,511,000 after buying an additional 18,066 shares during the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Bruker (BRKR) Expected to Announce Earnings of $0.22 Per Share” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2018/04/22/bruker-brkr-expected-to-announce-earnings-of-0-22-per-share.html.

Bruker Company Profile

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.